Protocols›Healing & recovery›Wolverine Starter
← Protocols
Athlete / performance · uptakeCommunity · convergenceNo approved clinical use

Wolverine Starter

Stack: BPC-157 + TB-500 · half dose
"The lighter, first-time version of the most-used healing stack on earth. Same honest ceiling as the full version: enormous uptake, no human trial of the combination."
GoalSoft-tissue recovery
Compounds2 · BPC-157 + TB-500
Humans exposed (est.)Very high — undocumented
StatusMHRA (UK): not licensed medicines — research material · FDA (US): status evolving (see below) · no human trials of the combination
In this stack — snapshot; tap through for the full molecule file
Provenance & evidence layers — of the combination, not the parts
Athlete / performance
Where / who
Community / athlete and clinic use as tagged above.
Use status
The default first healing stack.
Evidence it adds
Popularity / convention — not efficacy.
Basis: real-world uptake & convention — not trial data
US clinic · off-label compounding
Where / who
US functional-medicine, longevity & sports-medicine clinics — physician-prescribed via 503A/503B compounding pharmacies.
Track record
BPC-157 / TB-500: among the most commonly compounded peptides in US clinics until the Sept 2023 FDA Category 2 listing disrupted legitimate compounding — see the regulatory layer for current status.
Evidence it adds
Real-world clinical observation — physician-charted, supervised use. A genuine evidence tier, but observational: uncontrolled, unpublished, no registry, outside formal pharmacovigilance.
What it means
Off-label compounding under prescription — never an FDA-approved therapy. Removal from Category 2 is not approval.
Basis: US compounding-pharmacy practice · FDA Docket FDA-2025-N-6895
No approved clinical use
Clinical record
No country lists this exact combination as an approved therapy.
Human trials
No completed human trial of the combination. Animal / mechanistic only.
Basis required for a clinical-use tag: none found — absence shown, not hidden
Regulatory — read carefully
FDA (US)
BPC-157 / TB-500 were FDA Category 2 (compounding prohibited) 2023–Apr 2026; removed Apr 2026, under PCAC review (23–24 Jul 2026).
MHRA (UK)
Not licensed medicines. Sold as research material.
What it means
Removal from Category 2 is not approval — the compounding decision is pending.
Why it matters
No marketing authorisation = no pharmacovigilance; adverse events aren't formally tracked.
Basis: FDA Docket FDA-2025-N-6895 · PCAC 23–24 Jul 2026 — updates after the decision
Why this combination

A reduced-dose introduction to the BPC-157 + TB-500 pairing. The mechanistic rationale is the same as the full stack — and so is the evidence gap: preclinical only, no human trial of the combination.

Members only · the actionable depth
See exactly how it's run
Doses, cycle structure and what to monitor are part of membership. The provenance, evidence and exposure above are always free.
Get TiQ1 · Free →
Free · just create an account
Cycle shape — how it's typically structured, not a schedule to follow
Loading
build up
Maintenance
hold / taper
Off
stop / reassess
Convention from community use, not a prescription.
What's worth monitoring

With limited or no human safety data for this combination, there is no established marker set to monitor against — which is a reason for more caution, not less. Baseline bloods and a clinician conversation matter here. General information, not medical advice.

Combination evidence
Real-world uptake Very high

The default first healing stack.

Human efficacy None

Animal / mechanistic only.

Clinical observation Observational

A decade-plus of physician-supervised, charted use — meaningful real-world signal, with no commonly-reported serious adverse-event pattern. But uncontrolled, unpublished, held in private charts (no registry) and outside formal pharmacovigilance. Not controlled evidence.

The honest ceiling

High exposure, low evidence — the honest centre of every BPC/TB page.

Fast facts
Compounds

BPC-157 · TB-500

Humans exposed (est.)

Very high — undocumented.

UK strip

GREEN — research material